Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.…
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences (NASDAQ: JBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 15.31 USD on 20 November 2026, up 66.6% over 52 weeks. Its 52-week range is 8.825 USD to 28.00 USD: the price is 45.3% below the high and 73.5% above the low.
Its market capitalisation is 1.06B USD.
Jade Biosciences reports return on equity of -38.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 474.97M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 49.38 USD is 222.5% above the current price. The next earnings report is expected on 4 March 2027.